NASDAQ:RCPT - Receptos Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Receptos (NASDAQ:RCPT)

Receptos logoReceptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics in immune disorders. Its product candidates span three disease areas. It is developing its lead asset, ozanimod (formerly RPC1063), as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), which consists of Ulcerative Colitis (UC) and Crohn's Disease (CD). It is developing its second asset, RPC4046, for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis (EoE), for which it has been granted Orphan drug designation. Its research efforts include a preclinical program developing oral, small molecule, positive allosteric modulators (PAMs) of the glucagon-like peptide-1 receptor (GLP-1R) for the treatment of Type 2 Diabetes.

Receive RCPT News and Ratings via Email

Sign-up to receive the latest news and ratings for RCPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:RCPT
CUSIPN/A
Phone+1-858-6525700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-44.89%
Return on Assets-41.50%

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

Receptos (NASDAQ:RCPT) Frequently Asked Questions

What is Receptos' stock symbol?

Receptos trades on the NASDAQ under the ticker symbol "RCPT."

How were Receptos' earnings last quarter?

Receptos Inc (NASDAQ:RCPT) issued its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.09) by $0.20. View Receptos' Earnings History.

Has Receptos been receiving favorable news coverage?

Media coverage about RCPT stock has been trending positive on Wednesday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Receptos earned a coverage optimism score of 0.42 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 43.95 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Receptos?

Shares of RCPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Receptos?

Receptos' mailing address is 3033 Science Park Road, Suite 300, SAN DIEGO, CA 92121, United States. The biopharmaceutical company can be reached via phone at +1-858-6525700.


MarketBeat Community Rating for Receptos (RCPT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Receptos and other stocks. Vote "Outperform" if you believe RCPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Receptos (NASDAQ:RCPT) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/25/2016 forward)

Earnings

Receptos (NASDAQ:RCPT) Earnings History and Estimates Chart

Earnings by Quarter for Receptos (NASDAQ:RCPT)

Receptos (NASDAQ RCPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2015Q115($1.09)($1.29)$5.10 millionViewN/AView Earnings Details
3/3/2015Q414($1.19)($1.32)$2.06 millionViewN/AView Earnings Details
11/4/2014Q314($0.96)($1.19)$1.00 million$3.45 millionViewN/AView Earnings Details
8/12/2014Q214($0.85)($1.04)$1.28 million$1.10 millionViewN/AView Earnings Details
5/12/2014Q114($0.84)($1.01)$0.49 million$1.40 millionViewN/AView Earnings Details
3/5/2014($0.86)($0.86)$1.16 million$0.77 millionViewN/AView Earnings Details
10/30/2013Q313($0.61)($0.88)$1.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.56)($0.98)$0.54 million$1.24 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Receptos (NASDAQ:RCPT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Receptos (NASDAQ RCPT) Insider Trading and Institutional Ownership History

Insider Trading History for Receptos (NASDAQ:RCPT)

Receptos (NASDAQ RCPT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2015S. Edward TorresDirectorSell220,000$178.99$39,377,800.00View SEC Filing  
2/23/2015S. Edward TorresDirectorSell47,906$128.20$6,141,549.20View SEC Filing  
11/11/2014Faheem HasnainCEOSell200,000$109.47$21,894,000.00View SEC Filing  
11/11/2014Sheila GujrathiInsiderSell30,000$108.99$3,269,700.00View SEC Filing  
11/10/2014Chrysa MineoSVPSell30,000$109.73$3,291,900.00View SEC Filing  
11/10/2014Faheem HasnainCEOSell136,795$109.69$15,005,043.55View SEC Filing  
11/10/2014Marcus F BoehmCTOSell40,454$109.91$4,446,299.14View SEC Filing  
9/23/2014S. Edward TorresDirectorSell100,000$61.36$6,136,000.00View SEC Filing  
9/22/2014S. Edward TorresDirectorSell14,318$63.08$903,179.44View SEC Filing  
9/22/2014Sheila GujrathiInsiderSell30,000$61.45$1,843,500.00View SEC Filing  
9/19/2014S. Edward TorresDirectorSell169,570$62.55$10,606,603.50View SEC Filing  
9/18/2014S. Edward TorresDirectorSell91,513$62.77$5,744,271.01View SEC Filing  
9/17/2014David A HinkleCAOSell2,000$64.82$129,640.00View SEC Filing  
9/17/2014S. Edward TorresDirectorSell38,917$63.67$2,477,845.39View SEC Filing  
9/16/2014Graham K CooperCFOSell50,000$61.30$3,065,000.00View SEC Filing  
9/2/2014David A HinkleCAOSell2,000$52.80$105,600.00View SEC Filing  
8/13/2014David A HinkleCAOSell3,000$42.69$128,070.00View SEC Filing  
8/13/2014S. Edward TorresDirectorSell200,000$43.24$8,648,000.00View SEC Filing  
5/29/2014Kristina BurowDirectorSell153,698$29.74$4,570,978.52View SEC Filing  
5/21/2014S. Edward TorresDirectorSell424,068$25.26$10,711,957.68View SEC Filing  
5/15/2014S. Edward TorresDirectorSell90,075$27.37$2,465,352.75View SEC Filing  
5/14/2014Kristina BurowDirectorSell45,381$29.66$1,346,000.4613,333View SEC Filing  
1/3/2014William RastetterDirectorSell37,359$30.85$1,152,525.15View SEC Filing  
1/2/2014William RastetterDirectorSell27,581$30.29$835,428.49View SEC Filing  
12/6/2013Amir NashatDirectorSell170,000$26.70$4,539,000.00View SEC Filing  
12/5/2013William RastetterDirectorSell500,000$27.63$13,815,000.00View SEC Filing  
11/18/2013Ventures Fund 2007 Flagshipmajor shareholderSell230,787$24.75$5,711,978.25View SEC Filing  
11/15/2013Amir NashatDirectorSell169,315$24.96$4,226,102.40View SEC Filing  
5/14/2013Amir NashatDirectorBuy151,343$14.00$2,118,802.00View SEC Filing  
5/14/2013Ventures Fund 2007 L FlagshipMajor ShareholderBuy107,142$14.00$1,499,988.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Receptos (NASDAQ RCPT) News Headlines

Source:
DateHeadline
bluebird bio (BLUE) Names Mary Hedley to Board - StreetInsider.combluebird bio (BLUE) Names Mary Hedley to Board - StreetInsider.com
www.streetinsider.com - September 22 at 3:41 PM
bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors - Business Wire (press release)bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors - Business Wire (press release)
www.businesswire.com - September 20 at 8:17 AM
What Gilead Could Learn From Celgene - Seeking AlphaWhat Gilead Could Learn From Celgene - Seeking Alpha
seekingalpha.com - July 8 at 1:59 PM
Look Under The Hood: IWC Has 17% UpsideLook Under The Hood: IWC Has 17% Upside
www.thestreet.com - June 19 at 10:07 AM
Analysts Predict 20% Gains Ahead For IWCAnalysts Predict 20% Gains Ahead For IWC
www.thestreet.com - June 1 at 9:03 PM
3 Large-Cap Stocks for the Long Term3 Large-Cap Stocks for the Long Term
www.fool.com - May 30 at 7:10 PM
UPDATE 1-Celgenes multiple sclerosis drug succeeds in late-stage trialUPDATE 1-Celgene's multiple sclerosis drug succeeds in late-stage trial
www.businessinsider.com - May 23 at 9:40 AM
Celgene: Fears Over Revlimid Create A Buying OpportunityCelgene: Fears Over Revlimid Create A Buying Opportunity
seekingalpha.com - May 11 at 7:57 PM
The Implied Analyst 12-Month Target For IWCThe Implied Analyst 12-Month Target For IWC
www.thestreet.com - May 8 at 11:51 AM
Celgene Is A Must-Own StockCelgene Is A Must-Own Stock
seekingalpha.com - April 26 at 5:49 PM
Surprising Analyst 12-Month Target For IWCSurprising Analyst 12-Month Target For IWC
www.thestreet.com - April 12 at 6:35 PM
Multiple Abstracts Concerning MIS416 Mechanism of Action Accepted for Presentation at Upcoming American Academy of Neurologists MeetingMultiple Abstracts Concerning MIS416 Mechanism of Action Accepted for Presentation at Upcoming American Academy of Neurologists Meeting
au.finance.yahoo.com - March 7 at 7:20 PM
Insider Selling Picks Up as Market Volatility JumpsInsider Selling Picks Up as Market Volatility Jumps
247wallst.com - January 9 at 7:27 AM
Huge Biotech Trade Highlights Insider Selling as Market Hits Record HighsHuge Biotech Trade Highlights Insider Selling as Market Hits Record Highs
247wallst.com - January 9 at 7:27 AM
Celgene will buy drug developer Receptos for $7.32 billionCelgene will buy drug developer Receptos for $7.32 billion
www.latimes.com - January 9 at 7:27 AM
Is Celgene Transforming Itself With Mergers and Pacts?Is Celgene Transforming Itself With Mergers and Pacts?
247wallst.com - January 9 at 7:27 AM
Bioniz Therapeutics Appoints Paul Frohna M.D., Ph.D., Pharm. D., as Senior Vice President of Clinical DevelopmentBioniz Therapeutics Appoints Paul Frohna M.D., Ph.D., Pharm. D., as Senior Vice President of Clinical Development
www.prnewswire.com - December 20 at 7:10 PM
Is This a Potential $7 Billion Waste for Celgene Corporation?Is This a Potential $7 Billion Waste for Celgene Corporation?
www.fool.com - January 8 at 8:19 AM
RECEPTOS, INC. Files SEC form 10-Q, Quarterly ReportRECEPTOS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - July 30 at 6:12 AM

SEC Filings

Receptos (NASDAQ:RCPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Receptos (NASDAQ:RCPT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Receptos (NASDAQ RCPT) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.